" CFDA Having received granting of the ‘Green Channel’ by the CFDA, the Company has been undergoing an accelerated process with the relevant regulator and has successfully completed its existing clinical trials for the Prizma. Additional work is currently being finalised to capture further broader clinical data and medical anomalies, which is anticipated to be completed in May 2019 and will form part of the final regulatory documentation. In parallel, the Company is in progress with the regulatory processes for the G Medical Patch. The Company looks forward to providing its shareholders continual updates on the CFDA approval as further information from the regulator is received."
Are the Chinese approvals more exacting than other jurisdictions?
GMV Price at posting:
29.0¢ Sentiment: Hold Disclosure: Held
